New hope for Hard-to-Treat breast cancer: immune cocktails enter trial

NCT ID NCT03971409

Ongoing Disease control Sponsor: Laura Huppert, MD, BA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining immunotherapy (avelumab) with other drugs can shrink tumors in people with advanced triple-negative breast cancer that has spread or come back. About 145 participants will receive one of several drug combinations, including avelumab plus liposomal doxorubicin, with or without binimetinib, or avelumab plus sacituzumab govitecan. The goal is to see if these combinations improve response rates compared to standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: avelumab, liposomal doxorubicin, binimetinib, sacituzumab govitecan
What this could lead to: If successful, this could point toward more effective treatment options for people with advanced triple-negative breast cancer.
What could go wrong: This is an early phase 2 trial with a small number of participants. The drug combinations may not work better than existing treatments and could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm invasive breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INVASIVE BREAST CARCINOMA RECURRENT BREAST CARCINOMA STAGE III BREAST CANCER STAGE IIIA BREAST CANCER STAGE IIIB BREAST CANCER STAGE IIIC BREAST CANCER STAGE IV BREAST CANCER TRIPLE-NEGATIVE BREAST CARCINOMA UNRESECTABLE BREAST CARCINOMA

Contacts and locations

Locations

Abramson Cancer Center, University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Baylor College of Medicine

Houston, Texas, 77030, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke Cancer Institute

Durham, North Carolina, 27710, United States
Georgetown University

Washington D.C., District of Columbia, 20057, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
O'Neal Comprehensive Cancer Center

Birmingham, Alabama, 35294, United States
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

Baltimore, Maryland, 21218, United States
UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
University of California, San Francisco

San Francisco, California, 94143, United States
University of Chicago Medicine Comprehensive Cancer Center

Evergreen Park, Illinois, 60805, United States
Vanderbilt University Ingram Cancer Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.